La vendita allo scoperto per Nkarta dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Nkarta. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Nkarta (NASDAQ:NKTX) Azioni, Report sulle vendite allo scoperto

Nkarta

Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.

Nkarta Inc

This is an indefinite-delivery, indefinite-quantity contract where future orders will be solicited by DOE from those who received awards, including NFS. The minimum ordering guarantee is&nbsp;$2 million.

News

Contracts

BWXT

BWX Technologies Says NFS Subsidiary Was Selected By US Department of Energy As One Of The Successful Bidders For High-Assay Low-Enriched Uranium Deconversion Services

PLTR

SRFM

On October 2, 2024, Surf Air Mobility Issued To Palantir Technologies An Aggregate Of 1.27M Shares Of Common Stock For In-kind Services Worth $1.6M - Filing

Source: <a href="https://www.streetwisereports.com/article/2024/10/04/shallow-high-grade-uranium-mineralization-expands-at-co-s-project.html?utm_medium=feed">Streetwise Reports 10/04/2024</a>
Baselode Energy Corp. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/bsenf#OTC">BSENF</a>) has reported positive uranium assay results from three drill holes of the 2024 drill program at its Ackio prospect, located in the Athabasca Basin, Northern Saskatchewan. These results highlight the shallow depth and high-grade mineralization that continue to characterize the Ackio prospect.
Notably, drill hole AK24-119 intersected 0.28% U3O8 over 21.0 meters, including a high-grade section of 1.55% U3O8 over 1.5 meters at a depth of 141 meters. While drill hole AK24-118 returned 0.59% U3O8 over 8.5 meters, including 1.25% U3O8 over 1.5 meters at a depth of 153 meters.
CEO James Sykes commented in the press release, &quot;These results strengthen our confidence in Ackio. It&#39;s remarkable that, just over three years after discovering Ackio, we&#39;re still achieving better-than-expected grades and widths.&quot;
Baselode expects further assay results from the remaining 40 drill holes to be released after quality review and approval.
<h2>Looking At The Uranium Sector</h2>
The uranium market has experienced notable growth in recent years. As Kitco wrote on September 25, &quot;Despite recent market corrections, uranium and uranium-related equities have outperformed other asset classes over the long term&quot; with the U3O8 uranium spot price seeing significant rises in the last five years. The long-term fundamentals of the market remained strong, with Kitco noting that &quot;global uranium supply lagging behind demand&quot; could lead to higher prices as utilities are &quot;forced to secure long-term contracts.&quot;
<blockquote class="callOut left">Jeff Clark of The Gold Advisor expressed enthusiasm for the company in an October 3 update, stating that the results from the drill program were better than expected, with high-grade uranium intersected in two keyholes.</blockquote>
Chris Temple of The National Investor similarly commented on September 25, &quot;Uranium and nuclear power are clearly back, with long-term demand increasing, driven by significant developments like the restart of nuclear facilities.&quot;
He observed that the sector appeared to be moving past its consolidation phase. He advised, &quot;Now is the time to rebuild exposure to uranium and nuclear power.&quot;
The Financial Times, also writing on September 25, highlighted the impact of the ongoing geopolitical climate on uranium pricing, stating that &quot;the conversion and enrichment prices are reflecting a much bigger supply squeeze due to the Russia-Ukraine war and other factors.&quot; They also pointed to the increasing prices for nuclear fuel, suggesting that &quot;higher nuclear fuel prices are likely to continue as existing conversion facilities face delays.&quot;
<h2>Baselode&#39;s Catalysts</h2>
The Ackio prospect remains a strong catalyst for Baselode Energy&#39;s growth, as the shallow and high-grade uranium mineralization continues to yield favorable results. Baselode&#39;s exploration strategy focuses on near-surface, basement-hosted uranium, which offers the potential for low-cost extraction.
As highlighted in the company&#39;s investor presentation, the Ackio discovery includes nine uranium pods, with mineralization starting as shallow as 25 meters below the surface. The ongoing drilling campaign, which has completed over 30,000 meters since 2021, further enhances the company&#39;s resource potential. With over US$20 million in the treasury, Baselode is well-funded to continue advancing Ackio and other projects, including the Catharsis project currently in drilling.
<h2>What Third-Party Experts Are Saying</h2>
David Talbot, Managing Director at Red Cloud Securities, noted in a September 17 report that drilling at Ackio has &quot;continued to expand the mineralized footprint at Pods 1, 6, and 7&quot; highlighting that &quot;thirteen holes reported composite intervals of anomalous radioactivity between 11m and 42m in thickness.&quot;
In his report, Talbot rated the stock as a Buy and further projected the potential for &quot;8-10-12 million pounds of U3O8 at a grade of ~0.3% U3O8&quot; which aligns with typical grades found in the southeastern part of the Athabasca Basin.
Additionally, Jeff Clark of The Gold Advisor expressed enthusiasm for the company in an October 3 update, stating that the results from the drill program were better than expected, with high-grade uranium intersected in two keyholes. Clark observed that &quot;the stock popped on the news, on heavy volume, investors obviously liking the results.&quot;
He also pointed out that Baselode&#39;s shallow mineralization at Ackio could make future mining operations more economically viable, noting the project&#39;s competitive advantage compared to deeper deposits elsewhere in the Athabasca Basin.
<h2>Ownership and Share Structure</h2>
According to Refinitiv, Baselode has institutions holding 23.26% with Alps Advisors holding the bulk of it with 17.94%, followed by Vident Investment Advisory LLC at 2.97%. Management and Insiders hold 1.59%. The rest is retail.
The company has a market cap of US$12.63 million, according to Market Watch, with 131.51 free float shares. It trades in the 52-week range between US$0.0778 and US$0.4491.
Important Disclosures:
1) James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
2) This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports&#39; terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.

Penny Stocks

Small Cap

Events

Markets

Trading Ideas

BSENF

Shallow High-Grade Uranium Mineralization Expands at Co.'s Project

Osisko recorded preliminary revenues from royalties and streams of C$57.3 million&nbsp;during the&nbsp;third quarter&nbsp;and preliminary cost of sales (excluding depletion) of C$2.2 million, resulting in a quarterly cash margin&nbsp;of approximately C$55.1 million&nbsp;(or&nbsp;96.3%).
As at September 30th, 2024, Osisko&#39;s cash position was C$58.5 million.&nbsp;The net debt position as of September&nbsp;30, 2024 was reduced to C$22.2 million&nbsp;during the&nbsp;third quarter&nbsp;following debt repayments of C$27.3&nbsp;million.

Osisko Reports 18,408 Attributable Gold Equivalent Ounces In Q3 On Preliminary Basis

AstraZeneca (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/azn#NASDAQ">AZN</a>) announced that it has signed an exclusive license agreement with China-based CSPC Pharmaceutical Group Ltd for developing an early-stage, small molecule Lipoprotein (a) (Lp(a)) disruptor for helping patients with dyslipidaemia.
The latest agreement is likely to strengthen AstraZeneca&#39;s cardiovascular pipeline, which is being studied for treating various cardiovascular diseases.
Year to date, shares of AstraZeneca have rallied 14.1% compared with the industry&#39;s rise of 18.5%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/fa/80674.jpg?v=23295027" />
Image Source: Zacks Investment Research
<h2>More on AZN&#39;s Latest Agreement</h2>
Per the deal, AZN will make an upfront payment of $100 million to CSPC. The company is also entitled to pay up to $1.92 billion for further development and commercialization milestones plus tiered royalties to CSPC.
Per the latest agreement with CSPC, AstraZeneca will gain access to the latter&#39;s pre-clinical candidate, YS2302018, an oral Lp(a) disruptor, and develop the same for various cardiovascular diseases. The company will develop YS2302018 alone or in combination studies, including with the oral small molecule PCSK9 inhibitor, AZD0780.
Discovered by CSPC, YS2302018 has been shown to effectively prevent the formation of Lp(a), a form of low-density lipoprotein&nbsp;that plays a key role in transporting cholesterol in the bloodstream.
Per the company, the addition of YS2302018 to AZN&#39;s cardiovascular pipeline might help patients to more effectively manage their dyslipidaemia and cardiometabolic diseases.
<h2>AZN&#39;s Airsupra Meet Goal in BATURA Study</h2>
In a separate press release, AstraZeneca announced positive data from the phase IIIb BATURA study, which evaluated its pressurized metered-dose inhaler (pMDI), Airsupra (albuterol/budesonide).
Data from the study showed that treatment with Airsupra led to a statistically significant and clinically meaningful reduction in the risk of a severe exacerbation when used as an as-needed rescue medication in response to symptoms versus as-needed albuterol in patients with intermittent or mild persistent asthma. This was the primary endpoint of the BATURA study.
Airsupra is approved for as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and above in the United States. It is the first and only anti-inflammatory rescue medication for the given condition.
<h2>AZN&#39;s Zacks Rank &amp; Other Stocks to Consider</h2>
AstraZeneca currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are ANI Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/anip#NASDAQ">ANIP</a>), ADMA Biologics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adma#NASDAQ">ADMA</a>) and Alnylam Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alny#NASDAQ">ALNY</a>), each sporting a Zacks Rank #1 (Strong Buy) at present. In the past 60 days, estimates for ANI Pharmaceuticals&#39; 2024 earnings per share have moved up from $4.53 to $4.81. Earnings per share estimates for 2025 have improved from $5.38 to $5.86. Year to date, shares of ANIP have increased 1.3%.
ANIP&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 31.32%.
In the past 60 days, estimates for ADMA Biologics&#39; 2024 earnings per share have increased from 35 cents to 49 cents. Earnings per share estimates for 2025 have improved from 53 cents to 64 cents. Year to date, shares of ADMA have surged 346.5%.
ADMA&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 105.63%.
In the past 60 days, estimates for Alnylam&#39;s 2024 loss per share have narrowed from $1.20 to 63 cents. Loss per share estimates for 2025 have narrowed from 34 cents to 27 cents. Year to date, shares of ALNY have rallied 39.4%.
ALNY&#39;s earnings beat estimates in each of the trailing four quarters, with the average surprise being 108.53%.
<a href="https://www.zacks.com/stock/news/2347767/astrazeneca-inks-agreement-to-boost-cardiovascular-pipeline?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2347767">To read this article on Zacks.com click here.</a>

Biotech

Earnings

Earnings Beats

Large Cap

Mid Cap

Analyst Ratings

General

ADMA

ALNY

ANIP

AstraZeneca Inks Agreement to Boost Cardiovascular Pipeline

8 analysts have expressed a variety of opinions on NMI Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMIH#NASDAQ">NMIH</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $44.25, a high estimate of $48.00, and a low estimate of $40.00. Observing a 12.74% increase, the current average has risen from the previous average price target of $39.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1728421255_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of NMI Holdings by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Terry Ma</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$46.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Scott Heleniak</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$48.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Bose George</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$40.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Terry Ma</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$43.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Scott Heleniak</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$40.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Mark Hughes</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$47.00</td>
<td>$37.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to NMI Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of NMI Holdings compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of NMI Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of NMI Holdings's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/NMIH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on NMI Holdings analyst ratings.</a>
<h2>Get to Know NMI Holdings Better</h2>
NMI Holdings Inc through its subsidiaries provides private mortgage guaranty insurance. The company offers mortgage insurance, reinsurance on loans, and outsourced loan review services to mortgage loan originators. It serves national and regional mortgage banks, money center banks, credit unions, community banks, builder-owned mortgage lenders, Internet-sourced lenders, and other non-bank lenders. It protects lenders and investors from default-related losses on a portion of the unpaid principal balance of a covered mortgage.
<h3>NMI Holdings's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: NMI Holdings's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 13.62%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: NMI Holdings's net margin is impressive, surpassing industry averages. With a net margin of 56.8%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): NMI Holdings's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.58% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): NMI Holdings's ROA stands out, surpassing industry averages. With an impressive ROA of 3.02%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: NMI Holdings's debt-to-equity ratio is below the industry average. With a ratio of 0.2, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NMIH

In-Depth Examination Of 8 Analyst Recommendations For NMI Holdings

5 analysts have shared their evaluations of PennyMac Financial Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFSI#NYSE">PFSI</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $116.8, with a high estimate of $125.00 and a low estimate of $102.00. Marking an increase of 6.96%, the current average surpasses the previous average price target of $109.20. 
<img src="https://www.benzinga.com/files/images/story/2024/1728421248_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of PennyMac Financial Servs by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark Devries</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$125.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Jay McCanless</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Crispin Love</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$112.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>George Bose</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$102.00</td>
<td>$102.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to PennyMac Financial Servs. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of PennyMac Financial Servs compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of PennyMac Financial Servs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into PennyMac Financial Servs's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PFSI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on PennyMac Financial Servs analyst ratings.</a>
<h2>Get to Know PennyMac Financial Servs Better</h2>
PennyMac Financial Services Inc is a United States-based financial services company primarily engaged in mortgage lending. The company operates through three segments: production, servicing, and investment management. The company's production and servicing segment together form the mortgage banking business that includes mortgage loan origination, acquisition, and sale activities; while the investment management segment includes investment manager's activities, such as performing diligence, and managing acquired assets. The company generates the majority of revenue from its mortgage banking business.
<h3>Financial Insights: PennyMac Financial Servs</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: PennyMac Financial Servs's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 25.43%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 13.74%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): PennyMac Financial Servs's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.72% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): PennyMac Financial Servs's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.47%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: PennyMac Financial Servs's debt-to-equity ratio is below the industry average. With a ratio of 4.47, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PFSI

5 Analysts Have This To Say About PennyMac Financial Servs

10 analysts have expressed a variety of opinions on Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $88.3, a high estimate of $135.00, and a low estimate of $57.00. Marking an increase of 1.88%, the current average surpasses the previous average price target of $86.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1728421237_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Cloudflare. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew DeGasperi</td>
<td>Exane BNP Paribas</td>
<td>Announces</td>
<td>Underperform</td>
<td>$65.00</td>
<td>-</td>
</tr>
<tr>
<td>Aaron Samuels</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$99.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>John Difucci</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Sell</td>
<td>$57.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Yi Fu Lee</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>James Fish</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$83.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Alex Henderson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$135.00</td>
<td>$135.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>James Fish</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$82.00</td>
<td>$81.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Cloudflare. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cloudflare compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Cloudflare's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Cloudflare's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NET/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cloudflare analyst ratings.</a>
<h2>Delving into Cloudflare's Background</h2>
Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
<h3>Financial Milestones: Cloudflare's Journey</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Cloudflare displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 29.98%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Cloudflare's net margin excels beyond industry benchmarks, reaching -3.76%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Cloudflare's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -1.8%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Cloudflare's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.53%, the company showcases efficient use of assets and strong financial health.
Debt Management: Cloudflare's debt-to-equity ratio is below the industry average. With a ratio of 1.63, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Navigating 10 Analyst Ratings For Cloudflare

Medtronic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) underwent analysis by 15 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">12</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $93.33, along with a high estimate of $106.00 and a low estimate of $85.00. Observing a 2.71% increase, the current average has risen from the previous average price target of $90.87. 
<img src="https://www.benzinga.com/files/images/story/2024/1728421229_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Medtronic. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$98.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$104.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$92.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Perform</td>
<td>$94.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$106.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$87.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Danielle Antalffy</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$90.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$85.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$85.00</td>
<td>$88.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Medtronic. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Medtronic compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Medtronic's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Medtronic's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MDT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Medtronic analyst ratings.</a>
<h2>All You Need to Know About Medtronic</h2>
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for roughly 50% of the company's total sales.
<h3>Understanding the Numbers: Medtronic's Finances</h3>
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: Over the 3 months period, Medtronic showcased positive performance, achieving a revenue growth rate of 2.77% as of 31 July, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Medtronic's net margin excels beyond industry benchmarks, reaching 13.16%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Medtronic's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.12%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Medtronic's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 1.16%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Medtronic's debt-to-equity ratio is below the industry average at 0.58, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

15 Analysts Assess Medtronic: What You Need To Know

MSOS

Benzinga's Chicago Cannabis Conference Event "Vape Innovation Masterclass: Cost-Effective, Quality Tech For A Global Market" Begins

Stryker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>) has outperformed the market over the past 10 years by 4.03% on an annualized basis producing an average annual return of 15.84%. Currently, Stryker has a market capitalization of $134.45 billion. 
Buying $100 In SYK: If an investor had bought $100 of SYK stock 10 years ago, it would be worth $431.90 today based on a price of $352.83 for SYK at the time of writing.
<h3>Stryker's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728421222_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Stryker 10 Years Ago Would Be Worth Today

Howmet Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) has outperformed the market over the past 5 years by 23.87% on an annualized basis producing an average annual return of 38.01%. Currently, Howmet Aerospace has a market capitalization of $42.04 billion. 
Buying $100 In HWM: If an investor had bought $100 of HWM stock 5 years ago, it would be worth $507.99 today based on a price of $102.99 for HWM at the time of writing.
<h3>Howmet Aerospace's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728421217_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Howmet Aerospace 5 Years Ago Would Be Worth This Much Today

Twilio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TWLO#NYSE">TWLO</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $78.25, a high estimate of $110.00, and a low estimate of $65.00. This upward trend is apparent, with the current average reflecting a 3.64% increase from the previous average price target of $75.50.
<img src="https://www.benzinga.com/files/images/story/2024/1728421217_0_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Twilio. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Peter Weed</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$70.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Peter Weed</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$70.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Ryan Macwilliams</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$78.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$65.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>James Fish</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$77.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Twilio. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Twilio compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Twilio's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TWLO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Twilio analyst ratings.</a>
<h2>About Twilio</h2>
Twilio is a cloud-based communications platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
<h3>Financial Insights: Twilio</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Twilio's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 4.31%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Twilio's net margin is impressive, surpassing industry averages. With a net margin of -2.94%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.35%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Twilio's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.29% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Twilio's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.13.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TWLO

Twilio Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)

During the last three months, 12 analysts shared their evaluations of Rocket Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>), revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Rocket Companies and provided 12-month price targets. The average target is $15.54, accompanied by a high estimate of $20.00 and a low estimate of $11.50. This current average has increased by 20.65% from the previous average price target of $12.88. 
<img src="https://www.benzinga.com/files/images/story/2024/1728421209_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Rocket Companies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Terry Ma</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$14.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$19.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Douglas Harter</td>
<td>UBS</td>
<td>Raises</td>
<td>Sell</td>
<td>$14.00</td>
<td>$11.50</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$20.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Jay McCanless</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Douglas Harter</td>
<td>UBS</td>
<td>Raises</td>
<td>Sell</td>
<td>$11.50</td>
<td>$10.50</td>
</tr>
<tr>
<td>Mihir Bhatia</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$14.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Richard Shane</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$15.00</td>
<td>$13.50</td>
</tr>
<tr>
<td>Daniel Perlin</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$16.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Donald Fandetti</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Mark Devries</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$15.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Jay McCanless</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Rocket Companies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Rocket Companies compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Rocket Companies's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Rocket Companies's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RKT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Rocket Companies analyst ratings.</a>
<h2>About Rocket Companies</h2>
Rocket Companies is a financial services company that was originally founded as Rock Financial in 1985 and is currently based in Detroit. Rocket Companies offers a wide array of services and products but is best known for its Rocket Mortgage business. The company's mortgage lending operations are split between its direct-to-consumer lending, which sees borrowers accessing the company's lending arm directly through either its mobile app or website, and its partner network where mortgage brokers and other firms use Rocket's origination process to offer loans to their customers. The company has rapidly gained market share in recent years and is now the largest mortgage originator in the U.S. as well as the servicer for more than 2 million loans.
<h3>Breaking Down Rocket Companies's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Rocket Companies's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 5.38%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: Rocket Companies's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 0.1%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 0.2%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Rocket Companies's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.01%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Rocket Companies's debt-to-equity ratio is notably higher than the industry average. With a ratio of 9.1, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Latest Analyst Ratings For Rocket Companies

Investors may be worried about the future of the computer and technology sector, especially now that the former darling in the space, NVIDIA Co., is threatening to go into a correction in potentially the coming months. However, recent economic data suggests that there are other names in the space that are still worth taking another look into.
These stocks share the same characteristics that the manufacturing PMI index reported in its latest issue, so the odds are in favor of bulls in MicroStrategy Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mstr#NASDAQ">MSTR</a>), SAP (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sap#NYSE">SAP</a>), and even PTC Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ptc#NASDAQ">PTC</a>). These names would expose investors to the potential bull runs that could be seen in the cryptocurrency space as interest rate cuts work their way through Bitcoin and give it a run higher.
More than that, finance is now relying on software applications and increased technology implementation in daily operations, and this portfolio aligns investors with that rising demand trend as well. Not to mention the artificial intelligence capabilities needed in the product development and visualization space. Here are some of the fundamental and technical factors that place the odds in favor of these companies this cycle.
<h2>Key Fundamental Drivers Fueling the Computer Software Industry</h2>
The main drivers in the manufacturing PMI index are new orders, production, and inventories. Both new orders and output moved significantly over the last report, with inventories contracting aggressively, which signals upcoming demand across the sector.
But not all industries are made equal. The computer and electronics industries share the same dynamics, meaning investors can expect to see added and accelerating demand in the space. Even then, not all stocks are made equal, so ideally, those with premium forward P/E valuations and above-average earnings per share (EPS) growth will make for better candidates.
<h2>Long Candidate #1: MicroStrategy&#39;s Bitcoin</h2>
The last time the Federal Reserve (the Fed) cut interest rates, the price of Bitcoin more than doubled. This time, history could repeat itself, which is why MicroStrategy is increasing its balance sheet Bitcoin holdings so that the stock&#39;s book value will rise with it.
Even though the stock trades at 82% of its 52-week high, Wall Street analysts still believe it could reach a new high before the year ends. Benchmark leads the way with a price target set at $215 a share for MicroStrategy stock, which calls for a net upside of 30% from where the stock trades today.
Moreover, bearish traders have been forced to cover their short positions over the past quarter. MicroStrategy&#39;s short interest fell from $5.3 billion last quarter to $3.6 billion today, with a 2.9% contraction in the past month alone. Replacing these bears were some institutional buyers that were added recently.
Leading the buying were those at Park Avenue Securities, boosting their holdings by over 1,000% as of October 2024, bringing their net investment to $1.2 million today.
<h2>Long Candidate #2: Banks Need SAP</h2>
The financial sector is now increasingly dependent on technology and software for operations and risk management processes, and SAP stock is a major provider of these processes.
Since the stock has traded up to 95% of its 52-week high, investors can start to see the market reward the name with bullish momentum.
As of September 2024, analysts at Barclays decided to boost their price target on SAP stock to $252 a share and keep their &quot;Overweight&quot; ratings. To prove these analysts right, the stock would need to rally by 14.5% from its current level.
Wall Street analysts think that there will be additional demand for SAP&#39;s services in the coming months, so they forecast up to 52.7% EPS growth for the next 12 months. Based on these expectations, the market is now willing to pay a 34.5x forward P/E ratio over the industry&#39;s average of 28.4x.
<h2>Long Candidate #3: Labor Costs Aided By PTC&#39;s AI</h2>
Now that inflation is pushing the price of everything higher, especially labor, some companies may look to artificial intelligence to help them lower their costs and expand their margins and net profits. This is where the PTC expertise comes into play.
The stock is currently trading at 92% of its 52-week high, making for another bullish momentum play favoring investors. Based on the consensus price target, current analyst ratings suggest the stock could have a valuation as high as $200.2 a share, or a 12% upside from today&#39;s stock price.
With Wall Street EPS growth forecasts set at 19.8% for the next 12 months, investors now can see why the market is willing to pay a premium forward P/E valuation of up to 30.0x over the industry&#39;s average, as stocks that tend to grow above peers command these higher multiples.
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/massive-potential-3-tech-stocks-positioned-for-breakout-success/">Massive Potential: 3 Tech Stocks Positioned for Breakout Success</a>&quot; first appeared on MarketBeat.

Price Target

Management

Federal Reserve

Tech

MSTR

Massive Potential: 3 Tech Stocks Positioned for Breakout Success

After a 14-year wait, Red Dead Redemption and Undead Nightmare, are officially <a href="https://www.benzinga.com/general/gaming">heading to PC. </a>
Take-Two Interactive Software Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) Rockstar Games confirmed that both titles will launch on Oct. 29, 2024, across Steam, the Epic Games Store and the Rockstar Store.
See Also: <a href="https://www.benzinga.com/general/entertainment/24/06/39555552/rockstar-games-co-founder-reveals-why-gta-movie-never-made-sense">Rockstar Games Co-Founder Reveals Why GTA Movie &#8216;Never Made Sense&#8217;</a>
"For the first time in its storied legacy, John Marston's beloved journey can be experienced on PC in stunning, new detail," Rockstar <a href="https://www.rockstargames.com/newswire/article/o3314a19koo147/red-dead-redemption-and-undead-nightmare-coming-to-pc-october-29">said.</a>
<h1 class="wp-block-heading">New Features Tailored For PC Gamers</h1>
The PC port, developed by Double Eleven, who also worked on the 2023 PS4 and Nintendo Switch versions, is packed with enhancements. 
The game will feature native 4K resolution, up to 144Hz on compatible hardware, ultrawide and super ultrawide monitor support, HDR10, and full keyboard and mouse functionality. Additionally, Rockstar included Nvidia DLSS 3.7 and AMD FSR 3.0 upscaling technologies, making the experience even smoother for players on modern hardware.
Another upgrade is the inclusion of adjustable draw distances and shadow quality settings, offering players more customization to suit their systems. Nvidia DLSS Frame Generation, a feature designed to boost performance by increasing frame rates, will also be part of the package.
Despite these improvements, the PC version will only include the complete single-player campaigns for both Red Dead Redemption and Undead Nightmare. Multiplayer content, a popular feature in other Rockstar titles, will not be part of this release.
<h1 class="wp-block-heading">System Requirements For Red Dead Redemption PC</h1>
To run the game, players need at least the following specs:
<ul>
<li>Minimum: Intel Core i5-4670 / AMD FX-9590 processor, 8 GB RAM, Nvidia GeForce RTX 960 / AMD Radeon R7 360 graphics, and 12 GB of available storage.</li>
<li>Recommended: Intel Core i5-8500 / AMD Ryzen 5 3500X processor, Nvidia RTX 2070 / AMD RX 5700 XT graphics, with an SSD for optimal performance.</li>
</ul>
<h1 class="wp-block-heading">Pricing Still A Mystery</h1>
While pricing information has yet to be revealed, the community is buzzing with excitement. PC players have long felt sidelined by Rockstar's staggered approach to platform releases. 
Rockstar has previously delayed PC versions of games, such as Grand Theft Auto 5, which arrived on PC a year after its console debut. The same situation seems likely with Grand Theft Auto 6, for which no PC version has been announced yet.
The release of Red Dead Redemption on PC has sparked questions about what Rockstar has planned for future updates across other platforms. Players are speculating whether Red Dead Redemption 2 will see enhanced features on the upcoming PS5 Pro, particularly regarding 60fps and 4K resolution modes.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/05/39076138/you-wont-believe-the-best-gaming-soundtrack-ever-rolling-stones-top-25-revealed">You Won&#8217;t Believe The Best Gaming Soundtrack Ever: Rolling Stone&#8217;s Top 25 Revealed</a></li>
</ul>
Photo: Rockstar Games.

TTWO

Red Dead Redemption Finally Comes To PC: Everything You Need To Know

AMN Healthcare Services, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/amn#NYSE">AMN</a>) launched an innovative technology suite, WorkWise, last Wednesday. The suite is expected to unify the company&#39;s technologies into one single technology offering.
Per AMN Healthcare, WorkWise has been designed to streamline workforce processes by combining the capabilities of quantifying staffing demand with predictive scheduling, automated workforce management and enhanced clinician engagement using AI technology. The technology suite will likely empower healthcare systems to efficiently source the appropriate talent, while effectively managing costs.
The latest launch is expected to significantly boost AMN Healthcare&#39;s Technology and Workforce Solutions business and solidify its foothold in the healthcare space.
<h2>Likely Trend of AMN Stock Following the News</h2>
Following the announcement on Oct. 2, shares of the company moved nearly 2.8% south to $38.64 at yesterday&#39;s close.
Historically, the company has gained a high level of synergies from its product launches. Although the latest launch is likely to be beneficial for AMN&#39;s top-line growth going forward, the stock declined overall since the announcement despite a slight gain yesterday.
AMN Healthcare currently has a market capitalization of $1.47 billion. It has an earnings yield of 8.3%, higher than the industry&#39;s 3.6%. In the last reported quarter, AMN delivered an earnings surprise of 30.7%.
<h2>Significance of the Launch of AMN Healthcare&#39;s WorkWise</h2>
Per AMN Healthcare, WorkWise is completely integrated with healthcare organizations&#39; internal systems. This is expected to enable hospitals to optimize personnel for any type of job (permanent, per diem, contract), sourcing from internal and external talent, to reduce costs and predict staffing needs with greater precision. The solution will likely leverage automation and data analysis to provide insights and build engaged talent networks for effective workforce management and increased speed-to-fill for staffing needs.
AMN Healthcare&#39;s management believes that WorkWise will be an integrated solution with multiple capabilities that can work together to address complex workforce challenges in the healthcare industry. It is expected to provide a full end-to-end solution for hospitals and healthcare systems, which is built to adapt and evolve with their needs.
<h2>Industry Prospects in Favor of AMN</h2>
Per a report by Grand View Research, the global healthcare workforce management system market was valued at $1.9 billion in 2023 and is anticipated to witness a CAGR of 13.2% between 2024 and 2030. Factors like the shift toward value-based reimbursements and the increasing adoption of telehealth technologies and AI-driven analytics are likely to drive the market.
Given the market potential, the latest launch will likely provide a significant impetus to AMN Healthcare&#39;s business.
<h2>AMN Healthcare&#39;s Notable Launches</h2>
In August, AMN Healthcare launched Strategic Partnership Solutions. It aims to transform language access programs in healthcare organizations by providing comprehensive language services and strategic support to organizations.
In July, AMN Healthcare introduced a new teletherapy platform, Televate. Per the company, it has been designed to increase access to therapy services for students nationwide.
<h2>AMN&#39;s Share Price Performance</h2>
Shares of the company have lost 50.7% in the past year against the industry&#39;s 7.5% rise and the S&amp;P 500&#39;s 30.9% growth.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/04/80821.jpg?v=2132398298" />
Image Source: Zacks Investment Research
<h2>AMN Healthcare&#39;s Zacks Rank &amp; Key Picks</h2>
Currently, AMN carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are DaVita Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dva#NYSE">DVA</a>), Baxter International Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bax#NYSE">BAX</a>) and Boston Scientific Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>).
DaVita, sporting a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 17.5%. DVA&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 24.2%.
DaVita&#39;s shares have gained 74.8% compared with the industry&#39;s 31.7% rise in the past year.
Baxter, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 10%. BAX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average being 3.7%.
Baxter has gained 0.7% compared with the industry&#39;s 22.9% rise in the past year.
Boston Scientific, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 12.6%. BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 7.2%.
Boston Scientific&#39;s shares have rallied 62.4% compared with the industry&#39;s 22.9% rise in the past year.
<a href="https://www.zacks.com/stock/news/2347765/amn-stock-down-despite-workwise-launch-to-enhance-healthcare-delivery?cid=CS-BENZ-FT-analyst_blog|company_news_medical_sector-2347765">To read this article on Zacks.com click here.</a>

Health Care

Offerings

AMN Stock Down Despite WorkWise Launch to Enhance Healthcare Delivery

Barrington Research analyst Vincent Colicchio maintains Information Servs Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/III#NASDAQ">III</a>) with a Outperform and maintains $3.5 price target.

Barrington Research Maintains Outperform on Information Servs Gr, Maintains $3.5 Price Target

Cannabis

X's Alexa Alianiello Says There Are More Than 40M Posts About Cannabis On The Platform Every Year

Astera Labs Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) shares are trading higher in Tuesday&#8217;s after-hours session after the company announced new <a href="https://www.benzinga.com/pressreleases/24/10/b41238848/astera-labs-introduces-new-portfolio-of-fabric-switches-purpose-built-for-ai-infrastructure-at-clo">fabric switches for AI infrastructure</a>.
What Happened: After the market close on Tuesday, Astera Labs introduced a portfolio of switches designed for AI workloads in accelerated computing platforms deployed at cloud-scale.&nbsp;
The semiconductor-based connectivity solutions company said its Scorpio Smart Fabric Switch portfolio was optimized for AI dataflows to deliver maximum predictable performance per watt, high reliability, easy cloud-scale deployment, reduced time-to-market and lower ownership costs.
The new portfolio of fabric switches features the Scorpio P-Series for GPU connectivity and the Scorpio X-Series for back-end GPU clustering. The switches will expand Astera&#8217;s Intelligent Connectivity Platform, allowing it to serve as&nbsp;a smart, customizable connectivity backbone. 
&#8220;Hyperscalers are deploying highly specialized AI platforms at an unprecedented pace, scale, and complexity,&#8221; said Jitendra Mohan, CEO of Astera Labs.
&#8220;Scorpio offers energy efficient fabric solutions with predictable, secure, and high-performance data flows and extensive fleet management capabilities for accelerated AI infrastructure deployments at cloud-scale.&#8221;
See Also: <a href="https://www.benzinga.com/news/earnings/24/10/41236355/stocks-rally-as-oil-prices-tumble-tech-chipmakers-lead-as-traders-focus-on-ai-winners-before-earnin">Stocks Rally As Oil Prices Tumble; Tech, Chipmakers Lead As Traders Focus On AI Winners Before Earnings Season: What&#8217;s Driving Markets Tuesday?</a>
Astera Labs is a supplier of connectivity solutions for several tech giants. The company noted a comment from Brian Kelleher, senior vice president of GPU Engineering at NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), in the release.
&#8220;AI infrastructure requires the right balance of interconnect performance, efficiency and capabilities to enable accelerated computing for AI workloads at scale. The new Scorpio fabric switch portfolio can support NVIDIA accelerated AI infrastructure deployments across a wide variety of AI and HPC workloads,&#8221; Kelleher said.
ALAB Price Action: <a href="http://benzinga.com/quote/alab">Astera Labs shares</a> were up 3.49% in after-hours, trading at $54.81 at the time of publication Tuesday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

After-Hours Center

Movers

ALAB

NVDA

Astera Labs Stock Jumps After The Bell: What's Happening?

Nkarta ($NKTX), a biopharmaceutical company dedicated to the development of engineered natural killer (NK) cell therapies for cancer and autoimmune...

Nkarta's (NKTX) Making  Promising Progress in Its Clinical-Stage Journey

Nkarta GAAP EPS of -$0.34 beats by $0.13

TD Cowen analyst Yaron Werber maintained a Buy rating on Nkarta (NKTX – Research Report) today. The company's shares closed today at $4.97. Accordi...

TD Cowen Remains a Buy on Nkarta (NKTX)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Nkarta (NASDAQ:<a href="https://investorplace.com/stock-quotes/nktx-stock-quote/">NKTX</a>) just reported results for the second quarter of 2024.<ul><li>Nkarta reported earnings per share of -34 cents. This was above the analyst estimate for EPS of -47 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/nktx-stock-earnings-nkarta-for-q2-of-2024/">NKTX Stock Earnings: Nkarta Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NKTX Stock Earnings: Nkarta Beats EPS for Q2 2024

William Blair analyst Sami Corwin has maintained their bullish stance on NKTX stock, giving a Buy rating yesterday. I'm sorry, but I can't provide ...

Assessing Nkarta's Investment Potential: Buy Rating Justified by Sami Corwin's Analysis

In a report released today, Gil Blum from Needham maintained a Buy rating on Nkarta (NKTX – Research Report), with a price target of $13.00. Gil Bl...

Buy Rating on Nkarta Amid Promising Clinical Trials and Solid Financial Position

Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on Nkarta (NKTX – Research Report) and decreased the price target to $22.00 from ...

Nkarta's NKX019 Therapy: A Promising Future in Autoimmune Disease Treatment

Nkarta upgraded at Raymond James on valuation

Nkarta: NK Cell Therapy Biotech With Good Standing Targeting R/R NHL Patients

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on NKTX stock, giving a Buy rating on August 14. Daina Graybosch has g...

Buy Rating Affirmed for Nkarta Amid Strategic Focus and Promising Clinical Trials

BMYMP

GILD

NKTX

Press Releases

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Nkarta, Inc. (NKTX) on Behalf of Investors

Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis with First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications

Comments

Nkarta

Vendite allo scoperto

Nkarta (NASDAQ:NKTX) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO